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Abstract
Background: The blood brain barrier (BBB) is the bottleneck of brain-targeted drug development. Due to their
physico-chemical properties, nanoparticles (NP) can cross the BBB and accumulate in different areas of the central
nervous system (CNS), thus are potential tools to carry drugs and treat brain disorders. In vitro systems and animal
models have demonstrated that some NP types promote neurotoxic effects such as neuroinflammation and
neurodegeneration in the CNS. Thus, risk assessment of the NP is required, but current 2D cell cultures fail to mimic
complex in vivo cellular interactions, while animal models do not necessarily reflect human effects due to
physiological and species differences.
Results: We evaluated the suitability of in vitro models that mimic the human CNS physiology, studying the effects
of metallic gold NP (AuNP) functionalized with sodium citrate (Au-SC), or polyethylene glycol (Au-PEG), and
polymeric polylactic acid NP (PLA-NP). Two different 3D neural models were used (i) human dopaminergic neurons
differentiated from the LUHMES cell line (3D LUHMES) and (ii) human iPSC-derived brain spheroids (BrainSpheres).
We evaluated NP uptake, mitochondrial membrane potential, viability, morphology, secretion of cytokines,
chemokines and growth factors, and expression of genes related to ROS regulation after 24 and 72 h exposures. NP
were efficiently taken up by spheroids, especially when PEGylated and in presence of glia. AuNP, especially
PEGylated AuNP, effected mitochondria and anti-oxidative defense. PLA-NP were slightly cytotoxic to 3D LUHMES
with no effects to BrainSpheres.
Conclusions: 3D brain models, both monocellular and multicellular are useful in studying NP neurotoxicity and can
help identify how specific cell types of CNS are affected by NP.
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Background
Nanoparticles (NP) can be synthesized from different
materials and have generated increasing interest in
nanomedicine, mostly as drug delivery systems [1, 2].
NP capable of delivering drugs exhibit advantages such
as drug stability, increased bioavailability and reduced
drug concentrations required to reach the target, thus
decreasing side effects [3]. Some NP, including gold NP,
have the ability to cross the blood brain barrier (BBB)
and reach the central nervous system (CNS), providing
promising drug delivery systems (especially for the treat-
ment of CNS diseases [3–8]). NP surface modification
by adding specific targeting ligands can enhance their
BBB penetration and contribute for cellular uptake. NP
size, shape, surface, charge and modification with cell-
penetration peptides matter for cellular uptake and fate.
Commonly, smaller NPs are better internalized with
higher percentage of biodistribution [9–11] and display
more ability for BBB penetration and distribution in the
CNS [12, 13]. Positively charged NPs are more easily in-
ternalized than neutral and negatively NPs [14]. In this
sense, NP may serve as an important alternative for in-
vasive CNS procedures such as implantation of cathe-
ters, imaging and therapy of brain tumors, and
improvement of drug delivery [3, 15–17].
However, toxic effects of nanomaterials have been de-
scribed [1], including induction of oxidative stress, in-
flammation [18], DNA damage, and alterations in gene
expression [19]. We found earlier, for example, that co-
balt nanoparticles were able to induce cell transform-
ation, a hallmark of cancer, in contrast to cobalt ions
[20]. NP can also promote neurotoxic effects such as
neuroinflammation and neurodegeneration [21]. Despite
gold NP (Au-NP) being one of the mostly commonly
used nanomaterials (due to their versatility in particle
size and surface modification) and their biocompatibility
for applications such as drug and gene delivery [22], they
can induce toxicity in different cellular models [23]. In
addition, studies have shown that Au-NP induce apop-
tosis via caspase-dependent mechanisms as well as in-
crease cell susceptibility to apoptosis induced by other
agents [24, 25].
Polylactic acid NP (PLA-NP) is widely used as an al-
ternative for drug delivery, including CNS. PLA-NP
allow sustained therapeutic drug levels for longer pe-
riods due to their polymeric matrix that prevents drug
degradation, allowing better release kinetics. The surface
functionalization of PLA-NP with specific targeting li-
gands such as sialic acid and glycopeptides enhances
their ability to cross the BBB [5, 26]. For instance, chito-
san coating promote positive surface charge to PLA-NP,
resulting in enhanced cell uptake [27]. In addition, PLA-
NP exhibit biodegradable characteristics (unlike the me-
tallic ones) [28]. A detailed evaluation of neurotoxicity
mediated by different NP that are designed to be drug
carriers in the CNS, is necessary and will contribute to
the development of safer nanocarriers.
The current bioengineering revolution of cell culture
makes organotypic cell models, which overcome many
limitations of traditional cell culture, increasingly avail-
able [29]. Three-dimensional (3D) in vitro models are
the most novel approach in this development, as they
present closer cell-to-cell interactions, often include dif-
ferent cell types, and can better reproduce in vivo physi-
ology [30–33]. 3D CNS cultures have demonstrated
advantages compared to two-dimensional (2D) cultures,
such as increased cell survival and differentiation and
better reproduction of electrical activity [30, 34]. More-
over, NP delivery efficacy differs dramatically between
2D and 3D culture systems [35]. In addition, the use of
3D CNS models derived from human cells, especially
human pluripotent stem cells, provide more human-
relevant data compared to animal models, due to inter-
species differences [36]. Although, animal models used
for systemic toxicity, NP uptake, distribution in different
organs, internalization and stability studies, provide use-
ful and important information, the human physiology
and kinetics should be taking in account. Thus, more
advanced human relevant models such as organ-on-a-
chip technology, where several organotypic human cul-
tures are combined on a chip, are the future of drug de-
livery and nanotoxicity studies [37, 38]. Also, this will
scale-up the testing, since traditional animal testing is
time-consuming expensive and low-throughput.
Taking in account the advantages of 3D organotypic
cultures, increasing number of studies have used variety
of such models to study nanotoxicity and NP neurotox-
icity [39–43]. Hoelting and collaborators developed an
in vitro 3D neuronal model derived from human embry-
onic stem cell (hESC) and showed that polyethylene NPs
(PE-NP) penetrated into the neurospheres and impacted
gene expression at non-cytotoxic concentrations [42]. In
the same way, Zeng and collaborators developed an in
vitro 3D model of human neural progenitor cells and
showed that different types of polyamidoamine dendri-
mers NPs can penetrate into neurospheres, affecting cell
proliferation and migration through different pathways
[43]. To the best of our knowledge, toxicity of gold and
PLA-NP were not extensively studied in 3D brain
models. However, they represent a potential group of NP
that can be used for drug delivery in CNS, therefore,
studying their neurotoxicity is essential [44, 45]. The
toxicity of Au-NPs and PLA-NPs for CNS were previ-
ously investigated in vivo. Injection of Au-NP did not
promote morphological modifications or death in mice
retinal cells [46]. However, Au-NP treatment in rats in-
creased the number of GFAP- positive astrocytes in
hippocampus and cerebral cortex. In addition, an
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increasing diameter of cell body and length of foot
process of astrocytes in animals challenged with Au-NP
was observed [47]. PLA-NPs, polymeric NPs did not
show in vivo toxicity and considered to be relatively safe.
For example, Bejjani et al. have shown that these NPs
did not alter rat retinal structure or induced cell death
after intraocular injection [48]. However, it should be
noted that PLA-NP were not investigated as extensively
as Au-NP.
Both NPs are used for in vivo drug delivery. Previ-
ously, Au-NPs were used to IgG delivery in rabbit retina
[49] and as adjuvant to improve immunization in spinal
cord of injured rats [50]. PLA-NPs were used to carry
Gag p24 HIV-1 antigen to increase immune response in
mice [51] and T-cell responses on HIV-infected patients
[52]. PEG-PLA-NPs were also used to delivery beta-
methasone in cochlea, promoting attenuation of coch-
lear hair cells loss induced by traumatic noise in mice
[53].
Thus, in this study we focused on two types of NP: the
metallic Au-NP already widely used for drug delivery
and the biodegradable PLA-NP. We evaluated cellular
effects of Au-NP functionalized with sodium citrate
(Au-SC) and polyethylene glycol (Au-PEG), and PLA-
NP, using two human 3D CNS in vitro models: (i) 3D
LUHMES (Lund human mesencephalic) spheroids and
(ii) human iPSC-derived brain spheroids (BrainSpheres).
Both models have shown to be reproducible in content,
size and shape; forming spheroids of approximately 250
and 350 μm, respectively [54]. LUHMES is an immortal-
ized dopaminergic precursor cell line, derived from
healthy human 8-week-old embryonic mesencephalic tis-
sue, which rapidly differentiates into pure dopaminergic
neurons [55, 56]. BrainSpheres derived from human
iPSCs is a multicellular 3D brain model that contains
various types of neurons, astrocytes, and oligodendro-
cytes, and show spontaneous electrical activity and mye-
lination [54, 57]. By using these two models in parallel,
we can compare a single-cell type 3D model with a more
complex 3D system. After NP characterization, we eval-
uated NP uptake, morphological and molecular alter-
ations such as viability and mitochondrial membrane
potential, genes related to cytotoxicity and oxidative
stress and secretion of cytokines, chemokines, and
growth factors in both 3D models.
Results
NP characterization
In order to assess NP diameter, micrographs of Au-SC
(Fig. 1a), Au-PEG (Fig. 1b) and PLA-NP (Fig. 1c) were
acquired by TEM. Diameter of Au-SC, Au-PEG and
PLA-NP was 17.5 ± 1.4, 5.4 ± 0.7 and 67 ± 3 nm, respect-
ively (Fig. 1d). Hydrodynamic diameter of 6 μg/mL Au-
SC and 20 μg/mL PLA-NP was assessed by DLS in
medium without cells just after dilution and was 27 ± 1
and 116 ± 1.5 nm (0 h, 3D LUHMES medium) and 21 ± 2
and 62 ± 2 nm (0 h, BrainSpheres medium), respectively.
Although, Au-SC and PLA-NP were larger in 3D
LUHMES medium at 0 h, the diameters of these NP
remained stable after 24 and 72 h. In contrast, Au-SC
and PLA-NP diameters increased over time (Au-SC: 29
nm at 24 h to 38 nm at 72 h; PLA-NP: 99 nm at 24 h to
137 nm at 72 h) in BrainSpheres differentiation medium
(Fig. 1e). Due to the small diameter of Au-PEG (~ 5 nm),
they fall below the accurate range for DLS, as previously
informed by the Au-PEG manufacturer, and therefore
this measurement was not obtained for this NP type.
3D LUHMES and BrainSpheres production
3D LUHMES and BrainSpheres were produced by con-
stant gyratory shaking as previously described [54, 56,
58–60]. Both LUHMES and BrainSpheres are highly re-
producible in size (200–250 μm for LUHMES and 300–
350 μm for BrainSpheres) and cellular composition from
batch to batch and experiment to experiment. Due to
their small size they do not develop a necrotic core as
many bigger in size organotypic models do [54, 56, 58–
60]. That makes these two models very suitable to use
for neurotoxicological studies. At day 7 of differenti-
ation, 3D LUHMES expressing RFP (red fluorescent pro-
tein) exhibited neuronal morphology with several cell
projections and expressed markers of mature neurons,
such as MAP2, neurofilament and synaptophysin
(Fig. 2a). At 4 weeks of differentiation, BrainSpheres
expressed different neural markers consistent with phe-
notypes of neurons (β-tubulin, neurofilament, synapto-
physin, PSD95), astrocytes (GFAP) and oligodendrocytes
(O4), as shown in Fig. 2b).
NP uptake in 3D LUHMES and BrainSpheres
Since PLA-NP are conjugated to green fluorescent dye,
coumarin-6, we analyzed their penetration into the
spheroids by confocal imaging and flow cytometry. After
72 h exposure, uptake of 20 μg/mL PLA-NP by Brain-
Spheres (Fig. 3a) and 3D RFP-positive LUHMES (Fig.
3b) was visualized by confocal imaging. For better
visualization, BrainSpheres were stained for neuronal
(MAP2), astrocyte (GFAP) and oligodendrocyte (OLIG-
1) markers and show even distribution of PLA-NP
throughout spheroids reaching the core. The Additional
files 1 and 2 show the internalization of PLA in RFP-
positive LUHMES in more details (see Additional files 1
and 2).
In order to quantify the internalization and also dem-
onstrate concentration-dependent internalization, we
performed flow cytometry that allows to measure co-
localization of red signal from RFP protein in LUHMES
and green signal from PLA-NP. Thus, RFP-expressing
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3D LUHMES were exposed to 0, 0.2, 2, and 20 μg/mL
PLA-NP for 72 h, then spheroids were dissociated and
fixed for subsequent analysis of co-localization between
RFP (red) and PLA-NP (green) using flow cytometry.
Results indicated increased co-localization between
PLA-NP and RFP-expressing LUHMES cells in a
concentration-dependent manner. Only 7.2% cells
showed co-localization after exposure to 0.2 μg/mL while
96% cells co-localized with PLA-NP at 2 μg/mL,
reaching 100% at 20 μg/mL (Fig. 3c and Additional file 3
Figure S1A). In addition, we assessed internalization
with ImageStreamX Mark II imaging flow cytometer
(Amnis), which allows not only to analyze the shift of
the fluorescence intensities but also to obtain an image
of every cell in the flow and analyze intracellular
localization of NP. Trypan blue staining was included to
quench autofluorescence and fluorescence of NPs, which
might be just attached to the outer side of the
Fig. 1 NP characterization. Representative images obtained by TEM of a Au-SC, b Au-PEG and c PLA-NP. d Quantification of NP size by TEM. e Z-
average hydrodynamic diameter values of 6 μg/mL Au-SC and 20 μg/mL PLA-NP diluted in LUHMES and BrainSpheres culture media, analyzed by
DLS after 0, 24 and 72 h of incubation. Results are expressed as mean (±SD). Each experimental group corresponds to the analysis of three
independent experiments with three replicates. Statistical significance was analyzed by one-way ANOVA followed by Bonferroni’s multiple
comparisons post-test (**p < 0.01, ***p < 0.001). Scale bar a 100 nm, b 25 nm and c 200 nm
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membrane. Additional file 3: Figure S1B and C show
representative images of unstained RFP-LUHMES and
RFP- LUHMES treated with 20 μg/mL PLA NP for 24 h
respectively. The punctuated staining inside the cells in-
dicates internalization of PLA NP. Treatment with try-
pan blue did not shift the green fluorescence intensity
significantly (compare median of RFP + PLA (14,014) vs.
RFP + PLA + Trypan (11,989) suggesting that the green
fluorescence signal is coming from the inside of the cells
(Additional file 3: Figure S1D). Altogether, these data
showed that NP penetrated throughout both models; al-
though some NPs remained in the extracellular space,
some PLA-NP were internalized by cells throughout the
spheroids.
Au-SC and Au-PEG in both 3D models were assessed
by ICP-MS, a method to study cellular uptake of metallic
NP [61–64]. Our results showed Au-NP uptake in both
models after 24 and 72 h exposure. Uptake of both Au-
NP types was delayed in 3D LUHMES (increased after
72 h vs. 24 h exposure). In BrainSpheres, Au-SC uptake
Fig. 2 Confocal Images of a LUHMES after 7 days of differentiation, expressing RFP or stained with neuronal markers MAP2 (green), neurofilament
(red), synaptophysin (green); and b 4-week BrainSpheres expressing different neural cell type markers: β-III- tubulin/PSD95, neurofilament/
synaptophysin, GFAP/O4. Scale bars 100 μm for the first three panels and 50 μm for the last panel with higher magnification
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increased after 72 h compared to 24 h, while levels of in-
ternalization of Au-PEG at 24 and 72 h exposure time
points were similar (Fig. 3d). Although, due to method
limitations we cannot exclude the possibility of Au-NP
absorption on the surface of the cells. The viability tests
performed below indirectly confirm the presence of the
Au-NP within the cells.
Effects of NP on mitochondrial membrane potential
(MMP) and cell viability in both 3D human neural models
Both 3D LUHMES and BrainSpheres were exposed to
PLA, Au-SC, and Au-PEG at different concentrations
for 24 or 72 h, followed by analysis of MMP using Mito-
Tracker® Red CMXRos (Fig. 4a, b). After 24 h exposure
to 0.6 and 6 μg/mL Au-SC, MMP was reduced in both
models in a concentration-dependent manner (Fig. 4b).
After 72 h, a further decrease in MMP was observed in
3D LUHMES while BrainSpheres showed reduction only
at 6 μg/mL. After 24 h exposure, only the highest con-
centration of Au-PEG (20 μg/mL) led to reduced MMP
levels in 3D LUHMES, with no significant reduction at
72 h exposure. On the contrary, BrainSpheres showed a
strong concentration-dependent reduction of MMP after
24 and 72 h exposure to Au-PEG. PLA-NP reduced
MMP in 3D LUHMES at all concentrations after 24 h
exposure, which reversed at 0.2 μg/mL and further de-
creased at 2 and 20 μg/mL after 72 h exposure. MMP of
BrainSpheres was not affected by any of the PLA-NP
tested concentrations. Taken together, we observed
stronger acute than prolonged effects of tested NP on
Fig. 3 NP uptake by 3D LUHMES and BrainSpheres. Representative images acquired by confocal microscope after 72 h exposure to 20 μg/mL
PLA-NP (green) of a BrainSpheres stained with MAP2, GFAP, OLIG-1 (red) and Hoechst33342 (blue nuclei), with the Scale bars 100 μm (left panels)
and 25 μm (right panels); and b 3D RFP-LUHMES (red), PLA-NP (green), scale bar 20 μm. c Flow cytometry of RFP-LUHMES, treated with 0, 0.2, 2
and 20 μg/mL PLA-NP. Red and green fluorescence was quantified in FL2 and FL1 channels, respectively. The bars represent % of RFP/PLA double
positive cells in each sample. d Intracellular levels of Au in 3D LUHMES and BrainSpheres after 24 and 72 h exposure to 6 μg/mL Au-SC and
20 μg/mL Au-PEG quantified by ICP-MS. Results are expressed as mean (±SEM). Each experimental group corresponds to the analysis of three
independent experiments with three replicates. Student’s t-test was used to compare 24 and 72 h treatment groups (*p < 0.05, ***p < 0.001).
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mitochondria functionality in BrainSpheres, while 3D
LUHMES sensitivity to these NP was generally amplified
with increased exposure concentrations and time. These
data suggest different susceptibility of these 3D models to
the studied nanomaterials, most probably due to the dif-
ferences in cellular complexity of the models (Fig. 4a, b).
LDH release, a marker of cellular membrane dam-
age and cell death, was measured at the highest con-
centrations of NP. The viability of 3D LUHMES was
significantly affected (~ 25% cell death) by Au-PEG
and PLA-NP after 72 h exposure. The studied NP did
not affect BrainSpheres viability at the tested concen-
trations (Fig. 4c).
As expected, reduction in MMP was observed even
without significant LDH release. Since mitochondria
membrane depolarization occurs much earlier than cel-
lular membrane lysis in the cascade of cell death events,
it can be reversible [65–67], and, therefore, does not ne-
cessarily lead to cell death.
Morphology changes in 3D LUHMES and BrainSpheres
after NP treatment
The morphology of both spheroid models was analyzed
by scanning electron microscopy (SEM) after 72 h treat-
ment with the highest NP concentrations (Au-SC (6 μg/
mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL)).
Fig. 4 NP effect on MMP and cell viability in 3D human neural models. a Representative images of MitoTracker® staining in 3D LUHMES and
BrainSpheres after 24 and 72 h exposure to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL). Reduction in the Mitotracker
fluorescence intensity upon treatment with NP represents the reduction in uptake of the fluorescence probe due to impaired mitochondrial
membrane potential. b MMP levels in 3D LUHMES and BrainSpheres after 24 and 72 h exposures to Au-SC (0.06, 0.6 and 6 μg/mL), Au-PEG (0.2, 2,
20 μg/mL) and PLA-NP (0.2, 2 and 20 μg/mL) normalized to the untreated spheroids controls. c Percent of LDH release in 3D LUHMES and
BrainSpheres models after 24 and 72 h exposures to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL). ‘- Control’ corresponds to LDH
released from untreated spheroids. Results are expressed as mean (±SEM). Each experimental group corresponds to three independent
experiments imaging at least 20 spheroids. One-way ANOVA with Bonferroni’s multiple comparisons post-test was used for analysis of statistical
significance (*p < 0.05, **p < 0.01, ***p < 0.001)
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Morphology of 3D LUHMES was affected by Au-PEG
and PLA-NP, but not by Au-SC. Significant cell debris
attached to the spheroids and less neuronal projections
were observed (Fig. 5, depicted with arrowheads). Brain-
Spheres did not show any alterations under the investi-
gated conditions, which correlates with above
cytotoxicity data (Fig. 5).
NP effect on expression of oxidative stress related genes
in BrainSpheres
We further investigated changes in gene expression re-
lated to ROS regulation: SOD1, SOD2, NF2L2, GSTO1,
and NFR1 are involved in antioxidant responses and
CLEC7A is associated with ROS production and inflam-
mation. BrainSpheres and 3D LUHMES were exposed to
Au-SC (6 μg/mL), Au-PEG (20 μg/mL), and PLA-NP
(20 μg/mL) for 72 h, then gene expression was analyzed
by Real-Time qPCR. In BrainSpheres, SOD1 expression
was increased by Au-SC and Au-PEG, but not PLA,
whereas NF2L2 was increased only by Au-PEG. NFR1
expression was up-regulated by Au-PEG and PLA-NP,
while expressions of GSTO1 and CLEC7A were up-
regulated by all NP. SOD2 expression was not altered
upon NP challenge (Fig. 6). These data showed that the
exposure of BrainSpheres to NP increased expression of
genes related to oxidative stress protection in Brain-
Spheres, and the strongest effect was observed with Au-
PEG, in line with the higher uptake of this NP. The per-
turbations in 3D LUHMES were less dominant. No sig-
nificant effects on the expression of SOD1, SOD2 and
GSTO1 were observed; CLEC7A was undetermined.
NF2L2 was slightly elevated by AU-PEG, while NFR1 ex-
pression was downregulated by AU-SC and Au-PEG NP
(Additional file 4: Figure S2).
NP influence on release of chemokines, cytokines and
growth factors in 3D human neural models
Analysis of multiple secreted products from both 3D
models exposed to 6 μg/mL Au-SC, 20 μg/mL Au-PEG
or 20 μg/mL PLA-NP for 24 and 72 h showed alterations
in the levels of some mediators (Fig. 7). In general,
neural cells produce lower levels of chemokines and cy-
tokines compared to cells of the immune system, but
such levels are critical to maintaining their homeostasis
and, consequently, the microenvironment. Thus, any im-
balance may affect their physiological behavior [68].
From all conditions tested, Au-PEG had the strongest
effect on cytokines release in 3D LUHMES cultures. It
significantly downregulated the levels of all cytokines
tested. No significant changes in cytokine release were
observed in LUHMES cultures treated with Au-SC and
PLA-NP (Fig. 7a). TGF-β1, TGF-β2, and TGF-β3 levels
were not significantly altered in 3D LUHMES (Add-
itional file 5: Figure S3).
BrainSpheres were not as sensitive to Au-PEG with only
two cytokines (IL-10, IL12p70) and two growth factors
(bFGF, VEGF) downregulated in these cultures, while IL-
1ra was upregulated by Au-PEG and PLA-NP. In addition,
Au-SC reduced the levels of IL12p70 and VEGF in Brain-
Spheres (Fig. 7b). In BrainSpheres, TGF-β1 levels were re-
duced by Au-SC and Au-PEG after 72 h. These NP also
eliminated TGF-β3 in the first 24 h, but not after 72 h.
PLA-NP did not affect the levels of these soluble media-
tors (Fig. 8). Altogether, these data suggested different re-
sponses in the profile of chemokines, cytokines, and
growth factors to the studied nanomaterials in both
models, which are both devoid of immune cells. The very
low levels and frequent reductions in cytokine levels com-
pared to control are difficult to interpret. However, there
seems to some correspondence of cytokine patterns in re-
sponse to the NP between the two models, which corrob-
orates the findings. At this stage, these findings are
descriptive and mainly illustrate that cytokines could be
highly sensitive quantitative biomarkers for perturbation
of cells by NP. Further work is needed to understand the
mechanism and relevance of these changes.
Discussion
The use of NP as carriers promises advantages such as
better drug stability, bioavailability, improved dosing and
Fig. 5 Morphology of 3D LUHMES and BrainSpheres exposed to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL) for 72 h. Control
represents untreated spheroids. White arrowheads indicate cell debris. Scale bars 10 μm
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reduced side effects. Many NP drug delivery systems are
being developed, such as Au-NP conjugated to siRNA
against NADPH Oxidase 4, Au-NP carrying plasmid
DNA encoding for murine IL-2, PLA-NP carrying Gag
p24 HIV-1 antigen, B6 peptide conjugated to PEG-PLA-
NP encapsulating the neuroprotective peptide NAPV-
SIPQ to Alzheimer’s disease mice model, and others [51,
69–71]. However, nanotoxicity must be controlled before
administration [3, 72]. From the variety of NP used for
drug delivery, Au-NP are one of the most widely used
[73]. However, recent studies have shown their potential
to induce (neuronal) cytotoxicity and neuroinflammation
[23, 24]. PLA-NP emerged as an alternative for CNS
drug delivery due to their biocompatibility, biodegrad-
ability, and drug release kinetics [74]. Therefore, in this
study we decided to use Au-NP as a reference nanoma-
terial, since they are well established and described deliv-
ery system, and compare toxicity of Au-NP with an
alternative system – PLA-NP.
NP derived from different materials, including Au-NP
and PLA-NP are able to cross the BBB, especially if
modified with specific ligands, increasing the penetration
efficiency. They reach the CNS what makes them excel-
lent potential drug carriers for reaching the cerebral par-
enchyma [3, 5–8]. However, reported Au-NP toxicity to
the CNS includes apoptosis and alterations in retinal
layers structure, microglia activation, increase of neur-
onal excitability in CA1 region of hippocampus and the
potential to aggravate seizure activity [75–77]. The use
of PLA-NP for drug delivery is a relatively recent ap-
proach, showing positive results in treating hearing loss
and Alzheimer’s disease in animal models, without indu-
cing toxicity [53, 71]. Functionalization of NPs is import-
ant to ensure their colloidal stability and
biocompatibility. It should be kept in mind, that these
surface modifications may affect cellular toxicity. For in-
stance, cationic functionalization of Au-NPs is more
toxic than the neutral and anionic ones, and toxicity will
depend on the charge magnitude/intensity [78, 79]. An-
other study showed that citrate and biotin modified Au-
NPs were non-toxic up to higher concentrations,
whereas CTAB functionalization was toxic [80]. NP used
in this study were not functionalized with cytotoxicity
inducing cationic ligands. No cytotoxicity was reported
for PEG functionalization [81, 82].
Several 3D models have been developed and used to
study NP toxicity, drug discovery and delivery [31, 33,
35, 37–40]. Human-derived 3D neural in vitro models,
which mimic complex human CNS interactions are a
promising tool [54, 83–85] that can be applied to study
the potential cytotoxic effects of nanocarriers. The ad-
vantages of the two models presented here over the
Fig. 6 Effect of NP on expression of genes related to ROS regulation in BrainSpheres. Graphs showing the relative expression of SOD1, SOD2,
NF2L2, GSTO1, NFR1 and CLEC7A after exposure to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL) for 72 h normalized to the
expression of the genes in the untreated control spheroids. Data was collected from three independent experiments and represents fold changes
(FC ± SEM, n = 3). One-way ANOVA with Bonferroni’s multiple comparisons post-test was used to analyze the statistical significance (*p < 0.05,
**p < 0.01, ***p < 0.001)
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other existing in vitro organotypic brain models lie in
the high standardization of the spheroid generation pro-
cedures: the spheres generated with gyratory shaking are
very homogeneous in size, form and cellular compos-
ition as was shown in our previous publications [54, 56,
58, 59]. Although, other brain organotypic models are
more complex in representation of the organ morph-
ology [84, 85], we have chosen the models described
here because the homogeneity is a key feature in study-
ing toxicity. In the future, administration of NP in the
other brain organoids may confirm the findings pre-
sented here.
In this study we used Au-SC NP in concentrations up
to 6 μg/mL, Au-PEG and PLA up to 20 μg/mL. The dir-
ect comparison of NP brain concentrations in vivo with
in vitro nominal and final concentrations is challenging
Fig. 7 NP influence release of chemokines, cytokines and growth factors in 3D human neural models. Graphs showing the levels of different
secreted mediators after exposure to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL) for 24 and 72 h in comparison to untreated
control spheroids. a 3D LUHMES (MIP-1β, IL-10, IL-12p70, TNFα, bFGF and VEGF) and b BrainSpheres (IL-1ra, IL-10, IL-12p70, GM-CSF, bFGF and
VEGF). Data were collected from three independent experiments with three technical replicates and represents mean (± SEM). One-way ANOVA
with Bonferroni’s multiple comparisons post-test was used to analyze the statistical significance (*p < 0.05)
Leite et al. Particle and Fibre Toxicology           (2019) 16:22 Page 10 of 20
as well as quantification of final NP concentration in the
target organ. However, there are studies that quantified
the amounts of Au-NPs in the mice brain using ICP-
MS, the gold standard method for metallic detection in
cells and organs. Khlebtsov and Dykman, 2011 adapted
the results from [86] showing that after oral administra-
tion of 200 μg/mL Au-NPs with 4, 10 and 28 nm in size,
these NPs were detected and quantified in the brain:
from 10 ng/mL (4 nm Au-NPs) to 1 ng/mL (28 nm Au-
NPs) [87]. Comparing to our data, we used 4 nm Au-
NPs in vitro and detected up to 1000 ng in LUHMES
and up to 2000 ng in BrainSpheres per well (with around
50 LUHMES spheroids with 200–250 μm in diameter
and around 80 to 100 BrainSpheres with 300–350 μm in
diameter per well). (Fig. 3d). These NPs were detected in
lung, heart, kidney, spleen, liver, small intestine and
stomach in different concentrations [87]. It should be
kept in mind that the 200 μg/mL Au-NPs in the afore-
mentioned study were administrated via water bottles
for 7 days, without control of daily ingestion. It is pos-
sible that Au-NPs may have precipitated and deposited
on the bottom of the bottle that may result in lower
concentrations of NP in target organs. Jain et al., have
shown that rats treated intravenously with 60 μg/mL of
PLA-NP had particles in the brain [88] besides accumu-
lation in the liver, kidney, lungs, heart and spleen. How-
ever, since PLA NPs are not metallic and may degrade
quickly, they cannot be detected by ICP-MS, that makes
it difficult to measure their concentrations in the organs.
To characterize the interaction between NP, media
and cells in vitro, we assessed NP size, penetration
throughout the spheroids and internalization. Our NP
characterization showed that Au-SC and PLA-NP did
not change in size over time in LUHMES differentiation
medium. Although, immediately after resuspension of
NP in LUHMES differentiation medium, NP size was
higher than previously measured by TEM in water, they
were then stable in size for 24 and 72 h (Fig. 1c). How-
ever, in BrainSpheres differentiation medium, we ob-
served a gradual increase in NP size for both Au-SC and
PLA-NP. In both media, the immediate (3D LUHMES)
or delayed (BrainSpheres) increase in NP size can be at-
tributed to aggregation or the formation of a protein
corona due to NP interaction with proteins in cell cul-
ture medium. It is possible that proteins from the
medium supplements attach to the NP, affecting their
hydrodynamic analysis. More work is needed within the
characterization field to better predict how these media
alter NP physico-chemical properties. Due to the propri-
etary composition of cell culture supplements, further
analysis to identify these proteins was not possible.
However, a protein corona could facilitate cellular NP
uptake, as is known to occur in blood circulation [89].
Studying the composition of the protein corona would
Fig. 8 Influence of NP on release of TGF-β isoforms in BrainSpheres.
Graphs show the levels of secreted TGF-β1, TGF-β2 and TGF-β3 after
exposure to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP
(20 μg/mL) for 24 and 72 h in comparison to untreated control
spheroids. Each experimental group corresponds to the analysis of
three independent experiments with three replicates and represents
mean (± SEM). One-way ANOVA with Bonferroni’s multiple
comparisons post-test was used to analyze the statistical significance
(*p < 0.05, ***p < 0.001)
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be necessary to assess and improve drug delivery for
CNS therapies. A recent study showed that artificial apo-
lipoprotein E4 adsorption to NP forming corona in-
creases NP translocation through BBB, improving the
brain parenchyma accumulation threefold when com-
pared to undecorated particles [90].
A major question for the use of 3D organotypic cul-
tures to assess NP toxicity is, whether the NP can actu-
ally penetrate the spheroid and reach the inner cell
mass. The 3D models, studied here, were, indeed, able to
take up the three NP types. As quantified by flow cytom-
etry, PLA-NP were internalized by LUHMES in a
concentration-dependent manner, with 2 μg/mL being
sufficient to penetrate 96% of cells. These results support
the confocal images that showed PLA-NP in the core of
both 3D models. Au-SC uptake was similar in both 3D
models with increased levels after 72 h. Au-PEG showed
the same result as Au-SC in 3D LUHMES, but the up-
take in BrainSpheres was 5-fold higher after 24 h and
stabilized after 72 h. The differences in Au-PEG internal-
ization between the 3D models could be attributed to
the presence of glial cells in BrainSpheres that may take
up these NP more efficiently than neurons and/or regu-
late neuronal uptake as previously shown [91]. In fact,
PEG functionalization contributes to a better NP uptake
by neural cells, and their smaller diameter may be the
reason for higher intracellular levels compared to Au-SC
in BrainSpheres. This is in line with studies showing that
PEGylation increases NP accumulation in the brain
compared to non-PEG-coated NP [3, 92]. Therefore,
PEG-coating and the presence of glial cells facilitating
uptake could explain the high Au-PEG accumulation in
BrainSpheres in the first 24 h and their maintenance
until 72 h.
Due to the efficient NP internalization by neural cells
in the 3D models, their potential to induce nanotoxicity
needs to be considered. In 3D LUHMES, Au-SC but not
Au-PEG significantly reduced mitochondria function
(MMP). Au-PEG had only slight acute effects at the
highest concentration tested, which was no longer sig-
nificant after 72 h exposure. However, Au-PEG increased
LDH release, possibly due to the high contact surface
area of this NP that may contribute to neuronal lysis. In
BrainSpheres, MMP was significantly reduced by both
AuNP but no increase in LDH release was observed. In
this model, glial cells may be involved in the AuNP
clearance, reducing their availability and damage to
neuronal cells.
PLA-NP reduced MMP and increased LDH release in
3D LUHMES, but showed no effect in BrainSpheres.
The 3D LUHMES model is a monoculture model, con-
sisting only of dopaminergic neurons, and may display
higher susceptibility to harmful agents that induce mito-
chondrial damage, and cytotoxicity [93]. In fact, NP
cytotoxicity has shown to be lower when neurons and
astrocytes are co-cultured, compared to monocultures
[94]. The absence of neuroprotective glial cells, together
with the known susceptibility of dopaminergic neurons
to mitochondria depletion, could contribute to the tox-
icity observed in this model from all studied NP. On the
other hand, astrocytes in BrainSpheres as well as poly-
meric composition of PLA-NP may be critical to in-
crease NP biocompatibility and cell tolerance. It is
important to note that mouse prenatal exposure to NPs
induces neurotoxicity during development and astro-
cytes reactivity. Maternal inhalation of carbon black in-
creased GFAP levels in astrocytes from cortex and
hippocampus offspring [95]. Indeed, exposition of mice
from postnatal day 4–7 and 10–13, which is equivalent
to human third trimester, to ultrafine particle air pollu-
tion promoted inflammation, neurotoxicity, gliosis and
behavioral dysfunction [96]. In the line with that, we ob-
served an increase in glia marker - S100β - after expos-
ure of BrainSpheres to Au-PEG for 72 h (data not
shown), suggesting an induction of gliosis by Au-PEG
NP in BrainSpheres.
Mitochondrial dysfunctions are associated with ROS
production, promoting cell stress and death [97]. NP can
mediate this deregulation in neural cells [98]. Since
AuNP decreased MMP without cell viability loss in
BrainSpheres, we investigated the expression of genes in-
volved in antioxidant responses and ROS production.
Although all studied NP led to increased CLEC7A ex-
pression, related to ROS production and inflammation,
SOD1, NF2L2, GSTO1, and NFR1, related to antioxidant
responses in general, were increased by Au-PEG and
PLA-NP but not by Au-SC. This activation of antioxi-
dant genes may indicate that the cell activated antioxi-
dant response as a reaction to the NP challenge in
BrainSpheres. Different sources such as free radicals on
NP surface and redox group from NP functionalization
may cause the induction of ROS production and oxida-
tive stress, depending on NP type. The differences of
oxidative stress induction may activate different intracel-
lular signaling pathways such as the activation of tran-
scription factors and cytokines production and release
[99].
These results showed that the studied NP do not ne-
cessarily induce toxicity directly but are able to unbal-
ance cell physiology. Amongst these NP, Au-PEG had
the strongest effect, in line with their increased uptake.
In BrainSpheres, exposure to NP did not decrease via-
bility or lead to any apparent morphological alterations.
However, AuNP affected mitochondrial activity and in-
creased antioxidant genes with a possible activation of
cell survival programs, which may be sufficient to main-
tain cell viability and morphology. In contrast, 3D
LUHMES exposed to Au-PEG and PLA-NP showed
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morphological alterations on the surface of spheroids,
which was confirmed by cell death measured by LDH re-
lease. These results reinforce the impact of glial cells in
NP tolerance to toxic insults.
Glial and neuronal cells produce and secrete factors to
maintain survival. Some of them are considered pro-
inflammatory, but also important at physiological levels
for neuron-glia communication [100]. The level of these
factors can be altered in response to harmful agents. Au-
PEG reduced most detected cytokines, chemokines, and
growth factors in both 3D models. In 3D LUHMES, a re-
duction in MIP-1β, IL-10, IL-12p70, TNFα, bFGF and
VEGF levels are in line with the observed effects on via-
bility. In BrainSpheres, Au-PEG reduced the levels of IL-
10, IL-12p70, bFGF, VEGF, and TGF-β1, as well as in-
creased the IL-1ra levels. Au-SC affected fewer secreted
mediators, probably due to their smaller contact area
and low cell penetration rate compared to PEGylated
AuNP. In CNS, IL-12 is manly related to pathogenesis of
autoimmune diseases; VEGF to neurogenesis, neuronal
migration, neuroprotection, and blood vessel growth;
and TGF-β1 displays neuroprotective role and promotes
glial scar and fibrosis, induced by acute and chronic
brain injury [101–103]. IL-10 is an important anti-
inflammatory mediator. The reduced levels of such me-
diators suggest that AuNP in a first interaction with
neural cells may turn them susceptible to other subse-
quent harmful agents in the CNS. However, such alter-
ations together with reduced MMP were not sufficient
to induce cell death in BrainSpheres, possibly due to the
increased expression of antioxidant genes and the neuro-
protective role of astrocytes that may maintain cell
survival.
PLA-NP had minimal effects on secreted cytokines,
chemokines, and growth factors, restricted to IL-1ra in-
crease in BrainSpheres. IL-1ra binds to IL-1 receptor in
cell membranes, preventing IL-1 downstream signaling
and activation of inflammation [104]. This change, how-
ever, was small and may not be relevant for the cell
functionality. Further experiments will be conducted to
better elucidate the cytokine findings described here.
Altogether, we consider PLA-NP a stealth nanomater-
ial in multicellular 3D human neural models, containing
neuron and glial cells, without altering cell physiology
and functionality and suitable for carrying drugs of inter-
est in the CNS. In the future, we will address the cell-
specific responses to the NP within the BrainSpheres
such as reaction of glia cells (e.g., gliosis after expos-
ure to AU-PEG, we observed in our preliminary data)
. In addition, we will make use of our recently devel-
oped method of introducing microglia into the Brain-
Spheres [58]. This will allow us to look into the
inflammatory response such as cytokine release by
immune cells in more details.
Conclusions
This work showed that 3D brain spheroid models are
well suited to comparatively characterize NP neurotox-
icity. The simpler, single-cell model was more sensitive
to the toxic effects, in line with the lack of glia support
to neurons. The use of multiple models, which encom-
pass simplicity and physiological relevance, serves as tool
for more NP drug-delivery focused research (Fig. 9).
In conclusion, we have demonstrated that AuNP, the
most used nanocarrier, as well as PLA-NP, may be harm-
ful to pure dopaminergic neurons at the highest concen-
trations tested, which might represent a risk to
contribute to Parkinson’s disease development. In par-
ticular, in midbrain substantia nigra, where there is a
high number of dopaminergic neurons, the use of nano-
carriers should be carefully evaluated. However, this risk
might be overestimated as the model lacks neuroprotec-
tion provided by astrocytes. Thus, BrainSpheres, are
more appropriate model to study general neurotoxicity
because they contain the glia, which can provide such
neuronal support.
In a mixed population of neural cells within the Brain-
Spheres, the studied nanocarriers did not affect viability,
likely due to the presence of glial cells and their partici-
pation in brain clearance. Our findings showed that
AuNP promoted alterations in cell physiology that may
contribute to increased susceptibility to other subse-
quent harmful agents in the CNS. Therefore, the use of
AuNP as drug carrier in the CNS must be further evalu-
ated. PLA-NP induced minor alterations in BrainSphere




Spherical monodisperse NP diluted in ultrapure water
were used in this study. Au-SC were produced with 15 nm
nominal diameter through reduction of 1% tetrachloroau-
ric acid (Sigma Chem. Co.) by 1% sodium citrate aqueous
solution (Merck KGaA), based on the Turkevich method
revised by Kimling [105]. An Au-SC suspension was pro-
duced at 58 μg/mL and 1.7 × 1012 particles/mL concentra-
tion. Au-PEG 5-kDa at 1mg/mL Au mass concentration
(1015 particles/mL) were purchased from Nanocomposix
(batch JMW1410). Green-fluorescent Coumarin-6 PLA-
NP at 6.3 mg/mL polymer concentration (1.05 × 1013 par-
ticles/mL) were acquired from IBCP (Lyon, France). All
NP were stored and protected from light. Dimethyl sulfox-
ide (DMSO), paraformaldehyde (PFA) and cell lysis buffer
(CelLytic M) were from Sigma Aldrich.
Nanoparticle characterization
NP were sonicated for 5 min and particle suspensions
(10 μL of 1 μg/mL) were deposited on copper grids, air-
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dried and imaged in Tecnai G2 Spirit BioTwin 12 (Au-
SC and Au-PEG) or LEO 912 Omega (PLA-NP) (FEI)
transmission electron microscopes (TEM), both oper-
ated at 120 kV. NP diameter size were determined by
ImageJ software (https://imagej.nih.gov/ij/index.html
NIH). For analysis of NP hydrodynamic diameter, Au-SC
(6 μg/mL), Au-PEG and PLA-NP (20 μg/mL each NP)
were diluted in 3D LUHMES and BrainSpheres media
and incubated in cell culture flasks without cells follow-
ing the same conditions as for cell cultures. Then, 1 mL
of sample was transferred to an appropriate cuvette for
subsequent analysis of dynamic light scattering (DLS) in




Wild-type and red fluorescent protein (RFP) genetically
modified LUHMES human neuronal precursor cells
[106] were kindly provided by Prof. Marcel Leist (Uni-
versity of Konstanz) and maintained and cultured as pre-
viously described [55, 56, 107]. Briefly, flasks were pre-
coated with 50 μg/mL poly-L-ornithine and 1 μg/mL fi-
bronectin (both from Sigma Aldrich) for 12 h. Cells were
maintained in Advanced DMEM/F12 (ThermoFisher)
supplemented with 2mML-glutamine (Sigma Aldrich),
1x N2 (ThermoFisher) and 40 ng/mL recombinant basic
Fibroblast Growth Factor (bFGF, R&D Systems)
(LUHMES proliferation medium), and passaged every
2–3 days. For 3D neuronal differentiation, cells were
seeded in 6-well plates at 5 × 105 cells/well in 2 mL
Advanced DMEM/F12 supplemented with 2 mML-glu-
tamine, 1x N2, 1 mM dibutyryl cAMP (Santa Cruz),
2 μg/mL tetracycline (Sigma Aldrich) and 2 ng/mL re-
combinant human Glial cell line-Derived Neurotrophic
Factor (GDNF, R&D Systems) (LUHMES differentiation
medium). The spheroids were placed on an orbital
shaker (ES-X, Kuhner shaker) with 50mm orbit diam-
eter at 80 rpm in a humidified incubator at 37 °C and
10% CO2. As per the differentiation protocol [107], pac-
litaxel (Sigma Aldrich) was added on day 3 to block pro-
liferation and washed-out on day 5. On day 7, spheroid
size was quantified using SPOT software 5.0 (Diagnostic
Instruments Inc). 3D LUHMES were differentiated up to
10 days.
BrainSpheres
Neural progenitor cells (NPC) were differentiated from
iPSC [108] and kindly provided by Professor Hongjun
Song’s lab within our joint project [54]. iPSC were de-
rived from C1 (CRL-2097) fibroblasts purchased from
ATCC [108]. NPC were maintained in KO DMEM/F12
medium supplemented with 1x StemPro supplement
(ThermoFisher), 20 ng/mL human bFGF (Thermo-
Fisher), 20 ng/mL Epidermal Growth Factor (EGF, Ther-
moFisher), 4 mM L-Glutamine (ThermoFisher), 500
Units Penicillin and 500 μg Streptomycin (Thermo-
Fisher). Half of the medium was replaced every 24 h. For
BrainSpheres differentiation (previously described [54]),
cells were mechanically detached when reached 100%
confluence and seeded in 6-well plates at 2 × 106 cells in
2 mL Neurobasal Electro medium (ThermoFisher)
Fig. 9 Summary of the observed results in 3D LUHMES and 3D BrainSphere models exposed to the NP
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supplemented with B-27-electro (ThermoFisher), 10 ng/
mL Brain-Derived Neurotrophic Factor (BDNF) and 10
ng/mL GDNF (Gemini), 4 mM L-glutamine (Thermo-
Fisher), 500 Units Penicillin, and 500 μg Streptomycin
(ThermoFisher). Cells were placed on an orbital shaker
with 19 mm orbit diameter at 88 rpm into humidified in-
cubator at 37 °C and 5% CO2. Medium was replaced
every 48 h. After 4 weeks of differentiation, the Brain-
Spheres were used for the experiments. Spheroid size
was quantified using SPOT software 5.0 (Diagnostic In-
struments, Inc.).
NP treatment
NP stock suspensions were diluted in differentiation
media on the day of treatment to prepare following final
concentrations: 0.06, 0.6 and 6 μg/mL of Au-SC; 0.2, 2
and 20 μg/mL of Au-PEG and PLA nanoparticles. The
used Au mass concentrations were in the range of previ-
ous in vitro studies [75–77]. 3D LUHMES were treated
with NP on day 7 of differentiation for 24 or 72 h. Brain-
Spheres were treated with NP after 4 weeks of differenti-
ation for 24 or 72 h. Then, spheroid and supernatant
samples were collected for endpoint measurements.
Immunocytochemistry and confocal microscopy
3D cultures were fixed with 4% paraformaldehyde (PFA)
for 1 h, washed 3 times with PBS and incubated for 2 h
with blocking buffer (1% BSA, 5% goat serum, 0.15%
saponin (Sigma Aldrich)). Samples were incubated 48 h
with primary antibodies (1:200 mouse anti-MAP2
(Sigma Aldrich); 1:200 rabbit anti-GFAP (Dako) and 1:
200 mouse anti-Olig1 (Millipore), 1:200 mouse anti-
Synaptophysin (Sigma), 1:200 rabbit anti-PSD95 (Life
Technologies), 1:1500 β-III-tubulin (Sigma Aldrich), 1:
200 anti O4 (R&D Systems) diluted in blocking buffer)
at 4 °C, followed by three washing steps and incubation
with secondary antibodies (1:500 goat anti-mouse Alexa
fluor 488 or 1:500 goat anti-rabbit Alexa fluor 568, di-
luted in blocking buffer, Molecular Probes) overnight.
Then, samples were washed and incubated with Hoechst
33342 (1:10,000, Molecular Probes) for at least 1 h at
room temperature (RT). After three washing steps, the
samples were mounted on glass slides with Prolong
Gold-antifade reagent (Molecular Probes) for confocal
microscopy. Z-stacks started at the top of the sample
were taking. Images were obtained with Zeiss LSM-510
(Zeiss) and Leica SP5 (Leica) confocal microscopes with
identical time exposure and image settings.
Flow cytometry
3D RFP-expressing LUHMES treated with different con-
centrations of PLA-NP for 24 h or 72 h were trypsinized
with TryplE Express containing 4 units/mL DNase at
37 °C for 30 min on the shaker. 40 μg/mL Trypan Blue
was added to subset of the samples to quench NP fluor-
escence from outside the cells. Then, samples were ho-
mogenized using a 1 mL syringe with a 26G3/8 needle.
Cells were washed with PBS twice, fixed with 4% PFA
for 30 min and the co-localization between 3D RPF-
expressing LUHMES cells and PLA-NP green fluores-
cence was quantified using a FACSCalibur flow cyt-
ometer (BD) or with ImageStreamX Mark II imaging
flow cytometer (Amnis) (in this case cells were imaged
live). The instrument was calibrated using fluorescent
beads and wild-type LUHMES cells were used as nega-
tive control to set the gates.
Inductively coupled plasma mass spectrometry (ICP-MS)
AuNP stock solution was used to prepare the calibration
solutions through serial aqueous dilutions for ICP-MS
determination (NexION 300D, PerkinElmer). 1% (v/v)
nitric acid (Merck) and 10 μg/L rhodium from Perkin-
Elmer was added to the calibration solution, blank, and
samples to improve analytical performance. The Au197
isotope was measured. For quantification of intracellular
Au mass, spheroids of both models were treated for 24
or 72 h with Au-SC or Au-PEG. Then, spheroids were
collected and lysed (CelLytic M lysis buffer, Molecular
Probes) for analysis.
Mitochondrial membrane potential assay
After NP treatment, mitochondrial membrane potential
(ΔΨm, MMP) was analyzed using MitoTracker® Red
CMXRos (ThermoFisher), according to manufacturer’s
recommendations. After 45 min treatment with Mito-
Tracker Red CMXRos reagent, spheroids were fixed with
4% PFA for 1 h at RT, washed with PBS and mounted on
glass slides. Images were acquired with fluorescence
microscope (Olympus BX60) and red fluorescence inten-
sity was quantified by ImageJ software (https://imagej.
nih.gov/ij/index.html, NIH).
Lactate dehydrogenase (LDH) release assay
LDH release was determined by colorimetric CytoTox
96 Cytotoxicity Assay kit (Promega). As positive control,
spheroids were treated with 1% TX-100 for 30 min. After
NP treatments, 20 μL of supernatants were transferred
to 96-well plates followed by the addition of 20 μL of
substrate solution. After 30 min of incubation in the
dark at RT, 20 μL of stop solution was added to each
sample. Color development was proportional to the
number of cells with disruption of plasma membrane.
Absorbance was measured at 490 nm. For evaluation of
eventual colorimetric interference, NP diluted in culture
medium were incubated with LDH positive control and
substrate according to manufacturer’s instructions.
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Scanning electron microscopy (SEM)
Spheroids were fixed with 2.5% glutaraldehyde for 1 h at
RT. After three washing steps with PBS, samples were
postfixed with 1% osmium tetroxide for 90 min in the
dark, followed by three washing steps with 0.1M cacodi-
late buffer (pH 7.4) and distilled water. Samples were
gradually dehydrated, dried at the critical-point and fi-
nally vaporized with platinum. Photomicrographs were
obtained at 3 kV in a SEM Helios Nanolab 650 (FEI,
ThermoFisher).
RNA extraction and quantitative real-time polymerase
chain reaction (qRT-PCR)
Total RNA was extracted from 3D cultures after NP
treatments using Tripure isolation reagent (Roche) ac-
cording to Chomczynski and Sacchi [109]. RNA quantity
and purity was determined using NanoDrop 2000c
(ThermoFisher). One microgram of RNA was reverse-
transcribed using the M-MLV Promega Reverse Tran-
scriptase (Promega) according to the manufacturer’s rec-
ommendations. The expression of genes was evaluated
using specific TaqMan gene expression assays (Thermo-
Fisher). qRT-PCRs were performed using a 7500 Fast
Real Time system (Applied Biosystems). Relative mRNA
expression was calculated using the 2−ΔΔCt method
[110]. The analyzed genes were: SOD1 (Hs00533490_
m1), NF2L2 (Hs00975961_g1), NFR1 (Hs00602161_m1),
GSTO1 (Hs02383465_s1), CLEC7A (Hs01902549) and
SOD2 (Hs00167309_m1). β-actin (BrainSpheres) and
18S (LUHMES) were used as housekeeping gene.
Analysis of multiple secreted mediators
Determination of cytokines, chemokines and growth fac-
tors secreted by 3D LUHMES and BrainSpheres cultures
upon NP exposure was carried through Luminex (Austin
TX, USA) xMAP magnetic technology for the following
analytes: IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin,
bFGF, GCSF, GM-CSF, IFN-γ, IP-10, MCP-1 (MCAF),
MIP-1α, MIP-1β, PDGF-BB, RANTES, TNFα and VEGF,
and TGF-β1, TGF-β2 and TGF-β3. Analysis was per-
formed following the manufacturer’s recommendations.
Briefly, after calibration and validation of Bio-Plex Mag-
pix (Bio-Rad), reagent reconstitution and standard curve
preparation, magnetic beads were added to each well of
the assay plate. Each step was preceded by washing steps
using an automated Bio-Plex Pro wash station (Bio-Rad).
Then, samples, standard and controls were added,
followed by detection antibodies and streptavidin-PE. Fi-
nally, magnetic beads were re-suspended and read. The
number of analytes detected in culture medium without
spheres (background) was subtracted from the samples,
allowing to access the protein levels secreted by cultures.
Additional files
Additional file 1: Z-stack from RFP-LUHMES treated with PLA NP, dem-
onstrating internalization of NP. (GIF 4019 kb)
Additional file 2: 3D reconstruction of additional file 1 demonstrating
internalization of PLA NP in RFP-LUHMES model. (GIF 4152 kb)
Additional file 3: Figure S1. Flow cytometry analysis of RFP-LUHMES
exposed to PLA NP. (A) Dot plots of 3D LUHMES exposed to 0.2, 2 and
20 μg/mL PLA NP. Wild type LUHMES were used to set up the gates. (B)
and (C) image galleries generated by ImageStream X Marc II flow cyt-
ometer from untreated RFP-LUHMES and RFP-LUHMES treated with
20 μg/mL PLA respectively. Ch01 – phase contrast, Ch02 – green, Ch04 –
red and Ch06- site scater. (D) Histogram of green fluorescence intensity
in untreated RFP-LUHMES (red), RFP-LUHMES treated with 20 μg/mL PLA
(green) and RFP-LUHMES treated with 20 μg/mL PLA and subsequently
with 40 μg/mL of trypan blue (blue). Table shows the number of live cells
gated in each sample and median of the fluorescence intensity in each
sample. (TIF 1877 kb)
Additional file 4: Figure S2. Effect of NP on expression of genes
related to ROS regulation in 3D LUHMES. Graphs showing the relative
expression of SOD1, NF2L2, NFR1, GSTO1 and SOD2 after exposure to Au-
SC (6 μg/mL), Au-PEG (20 μg/mL) and PLA-NP (20 μg/mL) for 72 h normal-
ized to the expression of the genes in the untreated control spheroids.
Data was collected from two independent experiments with total eight
biological replicates and represents fold changes (FC ± SEM). Only four
replicates were used for Au-SC treated samples. One-way ANOVA with
Dunnett’s multiple comparisons post-test was used to analyze the statis-
tical significance. (TIF 86 kb)
Additional file 5: Figure S3. Influence of NP on release of TGF-β iso-
forms in 3D LUHMES. Graphs show the levels of secreted TGF-β1, TGF-β2
and TGF-β3 after exposure to Au-SC (6 μg/mL), Au-PEG (20 μg/mL) and
PLA-NP (20 μg/mL) for 24 and 72 h in comparison to the untreated con-
trol spheroids. Each experimental group corresponds to the analysis of
three independent experiments with three replicates and represents
mean (± SEM). (TIF 3028 kb)
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